Floatz logo

Revacept

Atherosclerosis

AdvanceCor GmbHPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Atherosclerosis cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
SIMVASTATIN
Northern California Institute of Research and Education
Phase 4BBB
ADVICOR COMPONENT NIACIN
University of Washington
Phase 4BB
Lipitor
Erasmus Medical Center
Phase 4BB
Plavix
Ewha Womans University Seoul Hospital
Phase 4BB

View all 49 →

Same molecule, other indications

Revacept is also rated in:

carotid stenosisDormant
B
Indicative ·
57 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
55 / 100
View asset →
thrombotic diseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →